Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Part of paid clinical trials in Danville, Pennsylvania.

Sponsor
Geisinger Clinic
Study ID
NCT00750555
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    150 mg per day orally until disease progression occurs, up to a maximum of 12 months

Study Details

Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent

Key Dates

First listed
Sep 10, 2008
Start date
Sep 30, 2008
Status verified
Feb 2019
Primary completion
Dec 31, 2009
Completion
Dec 31, 2009

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: 1

Primary Outcome Measure

One Year Disease Free [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Geisinger Health SystemDanvillePennsylvania17822-

Find similar trials in Danville, PA

By condition
Head and neck cancer
By specialty
OncologyENT
By research site
Geisinger Health System· Danville, PA

Related Studies